CSWGNCT04682483
Cardiogenic Shock Working Group Registry
At risk: Primary completion moved at least 1 year 11 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 16 → 22 locations
Notable Primary and study completion dates pushed to Dec 2027 Show 5 more changesShow less
- Enrollment increased: 5000 → 20000 participants
- Eligibility criteria shortened, about 13 words
- Secondary endpoints: details revised at 4 of 4 entries
- Site details revised at 1 of 16 sites
- Publications: details revised at 10 of 10 entries
- Notable Primary completion date: Jan 1, 2025 to Jan 1, 2026
- Study completion date: Jun 1, 2025 to Jun 1, 2026
- Site contacts updated at 1 of 16 sites
- Minor Collaborators revised (4)v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below. 1. Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP \< 60mmHg or a \>30mmHg drop in MAP from baseline, SBP \< 90mmHg or a \>30mmHg drop in SBP from baseline, Pulse \> 100, Cardiac Index \< 2.2, Cardiac Power Output ≤ 0.6 or PAPI \< 1.0. 2. Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets.
Drugs: Vasopressor, Inotrope
Devices: Acute Mechanical Circulatory Support Devices
Sites
22 sites in 1 country